Alexion CEO Ludwig Hantson (file photo)
Alexion bags a discount biotech buyout for $1.4B, branching out in new directions from its Soliris franchise
Alexion is taking a trip down to the discount basement for its next M&A deal. And this time the executive team wants to branch out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
